RBC Says Edgewise Investors Focus on '7500 Phase 3 Design
RBC says investors are focused on the upcoming Phase 3 design for Edgewise Therapeutics' '7500 in hypertrophic cardiomyopathy.
RBC says investors are focused on the upcoming Phase 3 design for Edgewise Therapeutics' '7500 in hypertrophic cardiomyopathy.